mTOR inhibition modulates vaccine-induced immune responses to generate memory T cells in patients with solid tumors

Background Perturbation of the mechanistic target of rapamycin (mTOR) pathway can instruct effector versus memory cell fate of tumor antigen-specific T cells in preclinical models. In this study, we sought to understand the impact of rapamycin (sirolimus), an mTOR inhibitor, on reprogramming vaccine...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Li Yan, Nina Bhardwaj, Tibor Keler, Kunle Odunsi, Song Liu, Junko Matsuzaki, Takemasa Tsuji, Mark Long, Thinle Chodon, Emese Zsiros, Protul Shrikant, Jianming Wang, Alan Hutson, Stephanie Blank, Amit Lugade, Richard Koya, Spencer R Rosario, Henry G Withers, Shashikant B Lele
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	BMJ Publishing Group 2025-03-01
Saila:	Journal for ImmunoTherapy of Cancer
Sarrera elektronikoa:	https://jitc.bmj.com/content/13/3/e010408.full
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!